Back
 OJCD  Vol.6 No.4 , December 2016
Conn’s Syndrome Secondary to Adrenal Adenoma
Abstract:
Primary hyperaldosteronism is not as uncommon as we thought, and by recent estimates the prevalance may be as high as 11% among hypertensives. We present a case of a 33 years old male patient came with a complaint of headache in occipital area & weakness in both lower limb since 4 weeks. The patient was a diagnosed case of hypertension and was already on tablet Atenolol (25 mg) once a day. At the time of admission, the patient was found to have a pulse of 96/min and blood pressure of 170/100 mm of Hg. Power was 3/5 for both right and left lower limbs. At the time of admission, serum potassium was 2.8. As a result, the patient was shifted to tablet Metroprolol and Amlodipine (50 + 5 mg) once a day. We also added tablet Cilnidipine (10 mg) and Telmisartan (80 mg) once a day and syrup Potklor thrice a day with water. The patient was sent for renal artery doppler, urine for metanephrines and vanillylmandelic acid, serum aldosterone, plasma aldosterone/plasma renin activity ratio (PAC/PRA ratio), urinary aldosterone, urinary cortisol and adrenocorticotrophic hormone level and computed tomography (CT) abdomen to rule out hyperaldostronism. Plasma aldosterone/plasma renin activity ratio, urinary aldosterone was high and CT abdomen revealed a solitary nodule in the left adrenal gland measuring 1.2 × 1.0 cm in maximum transverse diameter, which was suggestive of adrenal adenoma. Diagnosis of Conn’s syndrome secondary to adrenal adenoma was made. The patient was advised tablet Aldactone (25 mg) once a day and serum electrolytes were repeated which showed normalization with normal blood pressure.
Cite this paper: Fulara, S. and Fulara, N. (2016) Conn’s Syndrome Secondary to Adrenal Adenoma. Open Journal of Clinical Diagnostics, 6, 47-51. doi: 10.4236/ojcd.2016.64009.
References

[1]   Funder, J.W., Carey, R.M., Mantero, F., et al. (2016) The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101, 1889.
http://dx.doi.org/10.1210/jc.2015-4061

[2]   Douma, S., Petidis, K., Doumas, M., et al. (2008) Prevalence of PRIMARY hyperaldosteronism in Resistant Hypertension: A Retrospective Observational Study. The Lancet, 371, 1921.
http://dx.doi.org/10.1016/S0140-6736(08)60834-X

[3]   Mattsson, C. and Young Jr., W.F. (2006) Primary Aldosteronism: Diagnostic and Treatment Strategies. Nature Clinical Practice Nephrology, 2, 198-208.
http://dx.doi.org/10.1038/ncpneph0151

[4]   Sawka, A.M., Young, W.F., Thompson, G.B., et al. (2001) Primary Aldosteronism: Factors Associated with Normalization of Blood Pressure after Surgery. Annals of Internal Medicine, 135, 258-261.
http://dx.doi.org/10.7326/0003-4819-135-4-200108210-00010

[5]   Ghose, R.P., Hall, P.M. and Bravo, E.L. (1999) Medical Management of Aldosterone-Producing Adenomas. Annals of Internal Medicine, 131, 105-108.
http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00005

[6]   Riester, A. and Reincke, M. (2015) Progress in Primary Aldosteronism: Mineralocorticoid Receptor Antagonists and Management of Primary Aldosteronism in Pregnancy. European Journal of Endocrinology, 172, R23.
http://dx.doi.org/10.1530/EJE-14-0444

 
 
Top